Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Hepatitis

  Free Subscription


Articles published in J Viral Hepat

Retrieve available abstracts of 227 articles:
HTML format



Single Articles


    December 2022
  1. NATHANI R, Leibowitz R, Giri D, Villarroel C, et al
    The Delta Delta: Gaps in Screening and Patient Assessment for Hepatitis D Virus Infection.
    J Viral Hepat. 2022 Dec 2. doi: 10.1111/jvh.13779.
    PubMed     Abstract available


  2. MUTIMER D, Elsharkawy A, Hathorn E, Arunkumar S, et al
    Age, ethnicity and proximity to clinic determine retention in care of chronic hepatitis B patients.
    J Viral Hepat. 2022 Dec 2. doi: 10.1111/jvh.13775.
    PubMed     Abstract available


  3. KOFFAS A, Mak LY, Kennedy PTF
    Hepatitis delta virus: Disease assessment and stratification.
    J Viral Hepat. 2022 Dec 2. doi: 10.1111/jvh.13777.
    PubMed     Abstract available


  4. FELD JJ, Forns X, Dylla DE, Kumada H, et al
    Safety analysis of glecaprevir/pibrentasvir in patients with markers of advanced liver disease in clinical and real-world cohorts.
    J Viral Hepat. 2022;29:1050-1061.
    PubMed     Abstract available


    November 2022
  5. HYDE Z, Roura R, Signer D, Patel A, et al
    Evaluation of a Pilot Emergency Department Linkage to Care Program for Patients Previously Diagnosed with Hepatitis C.
    J Viral Hepat. 2022 Nov 28. doi: 10.1111/jvh.13774.
    PubMed     Abstract available


  6. PERAZZO H, Silva MST, Coutinho C, Peixoto EM, et al
    Monkeypox outbreak as an opportunity to identify new cases of HCV infection in limited resource settings.
    J Viral Hepat. 2022 Nov 10. doi: 10.1111/jvh.13771.
    PubMed    


  7. LEE C, Emeto TI, Walsh N
    Prevalence of hepatitis B virus amongst refugees, asylum seekers and internally displaced persons in low- and middle-income countries: a systematic review.
    J Viral Hepat. 2022 Nov 10. doi: 10.1111/jvh.13770.
    PubMed     Abstract available


  8. LI G, Zhang P, Zhu Y
    Artificial liver support systems for hepatitis B virus-associated acute-on-chronic liver failure: A meta-analysis of the clinical literature.
    J Viral Hepat. 2022 Nov 3. doi: 10.1111/jvh.13767.
    PubMed     Abstract available


  9. GIRI S, Agrawal D, Afzalpurkar S, Gopan A, et al
    Tenofovir Versus Entecavir for Tertiary Prevention of Hepatocellular Carcinoma in Chronic Hepatitis B Infection After Curative Therapy: A Systematic Review and Meta-Analysis.
    J Viral Hepat. 2022 Nov 2. doi: 10.1111/jvh.13766.
    PubMed     Abstract available


  10. HWANG SY, Yoo SH, Chang HY, Kim S, et al
    Baseline and on-treatment HBcrAg levels as predictors of HBeAg seroconversion in chronic hepatitis B patients treated with antivirals.
    J Viral Hepat. 2022 Nov 2. doi: 10.1111/jvh.13765.
    PubMed     Abstract available


    October 2022
  11. BITTENCOURT PL, Iasi MDSF, Viana MV, Crespo DM, et al
    Poor linkage to care may compromise the brazilian plan for hepatitis c elimination.
    J Viral Hepat. 2022 Oct 27. doi: 10.1111/jvh.13762.
    PubMed     Abstract available


  12. CASEY JL, Dore GJ, Grebely J, Matthews GV, et al
    Hepatitis C Virus-Specific Immune Responses Following Direct Acting Antivirals Administered During Recent Hepatitis C Virus Infection.
    J Viral Hepat. 2022 Oct 27. doi: 10.1111/jvh.13761.
    PubMed     Abstract available


  13. AGARWAL K, Xu J, Gane EJ, Nguyen TT, et al
    Safety, pharmacokinetics, and antiviral activity of ABI-H2158, a hepatitis B virus core inhibitor: a randomized, placebo-controlled Phase 1 study.
    J Viral Hepat. 2022 Oct 27. doi: 10.1111/jvh.13764.
    PubMed     Abstract available


  14. CHADHA N, Turner A, Sterling RK
    Prevalence and predictors of abnormal alanine aminotransferase in patients with HCV who have achieved SVR.
    J Viral Hepat. 2022 Oct 27. doi: 10.1111/jvh.13763.
    PubMed     Abstract available


  15. SALPINI R, D'Anna S, Piermatteo L, Svicher V, et al
    Novel concepts on mechanisms underlying Hepatitis Delta virus persistence and related pathogenesis.
    J Viral Hepat. 2022 Oct 18. doi: 10.1111/jvh.13755.
    PubMed     Abstract available


  16. SQUIRES KE, Ogilvie L, Jucov A, Anastasiy I, et al
    A Randomized Phase 1b Trial of the Active Site Polymerase Inhibitor Nucleotide ATI-2173 in Patients With Chronic Hepatitis B Virus Infection.
    J Viral Hepat. 2022 Oct 6. doi: 10.1111/jvh.13753.
    PubMed     Abstract available


  17. HALL EW, Gounder P, Angles J, Nelson NP, et al
    Evaluating the Cost-Effectiveness of Hepatitis B Vaccination Strategies in High-impact Settings for Adults.
    J Viral Hepat. 2022 Oct 6. doi: 10.1111/jvh.13759.
    PubMed     Abstract available


  18. HEO M, Pericot-Valverde I, Niu J, Norton BL, et al
    More intensive hepatitis C virus care models promote adherence among people who inject drugs with active drug use: The PREVAIL Study.
    J Viral Hepat. 2022 Oct 5. doi: 10.1111/jvh.13756.
    PubMed     Abstract available


  19. MENDIZABAL M, Thompson M, Gonzalez-Ballerga E, Anders M, et al
    Implementation of a re-linkage to care strategy in patients with chronic hepatitis C who were lost to follow-up in Latin America.
    J Viral Hepat. 2022 Oct 5. doi: 10.1111/jvh.13758.
    PubMed     Abstract available


  20. BRYCE K, Smith C, Rodger A, Macdonald D, et al
    Falling treatment uptake in the hepatitis C care cascade is a growing threat to achieving elimination.
    J Viral Hepat. 2022 Oct 5. doi: 10.1111/jvh.13757.
    PubMed     Abstract available


    September 2022
  21. QIU LX, Huang Y, Quan JL, Bi ZF, et al
    The prognosis of hepatitis E infection in patients with chronic liver disease: a meta-analysis.
    J Viral Hepat. 2022 Sep 30. doi: 10.1111/jvh.13754.
    PubMed     Abstract available


  22. CAREY I, Christiana M, Marie-Ange M, Teresa B, et al
    Universal versus targeted screening for HCV infection in pregnancy in a diverse, multi-ethnic population: universal screening is more comprehensive.
    J Viral Hepat. 2022 Sep 22. doi: 10.1111/jvh.13752.
    PubMed     Abstract available


  23. CHOU C, Veracruz N, Chitnis AS, Wong RJ, et al
    Risk of Drug Induced Liver Injury in Chronic Hepatitis B and Tuberculosis Co-infection: A Systematic Review and Meta-Analysis.
    J Viral Hepat. 2022 Sep 22. doi: 10.1111/jvh.13751.
    PubMed     Abstract available


  24. MCDANIEL K, Utz AE, Akbashev MY, Fuller K, et al
    Safe co-administration of direct-acting antivirals and direct oral anticoagulants among patients with hepatitis C virus infection: an international multicenter retrospective cohort study.
    J Viral Hepat. 2022 Sep 14. doi: 10.1111/jvh.13750.
    PubMed     Abstract available


  25. DONG C, Song Z, Sun C, Wang K, et al
    HBsAg Seroconversion in De Novo Hepatitis B Virus Infected Pediatric Liver Transplant Recipients with Antiviral Therapy.
    J Viral Hepat. 2022 Sep 12. doi: 10.1111/jvh.13749.
    PubMed     Abstract available


  26. QI T, Zhu C, Wang J, Li B, et al
    MELD Score <18 Rule out 28-day ACLF Development among Inpatients with Hepatitis B Related Previous Compensated Liver Disease.
    J Viral Hepat. 2022 Sep 8. doi: 10.1111/jvh.13747.
    PubMed     Abstract available


  27. YANG AH, Yardeni D, Hercun J, Kleiner DE, et al
    Shear Wave Elastography: How well does it perform in Chronic Hepatitis D Virus Infection?
    J Viral Hepat. 2022 Sep 5. doi: 10.1111/jvh.13745.
    PubMed     Abstract available


  28. HARTL L, Jachs M, Bauer D, Simbrunner B, et al
    An HCV hotline facilitates Hepatitis C elimination during the COVID-19 pandemic.
    J Viral Hepat. 2022 Sep 5. doi: 10.1111/jvh.13746.
    PubMed     Abstract available


  29. REYNOLDS L, Franco R, Prado M, Rodgers JB, et al
    Hepatitis C Active Viremia Over Time in an ED-based Testing Program: Impact, Disparities,.
    J Viral Hepat. 2022 Sep 5. doi: 10.1111/jvh.13744.
    PubMed     Abstract available


  30. JHA AK
    Hepatitis of unknown origin in children: Updated evidence and concise review.
    J Viral Hepat. 2022 Sep 5. doi: 10.1111/jvh.13743.
    PubMed     Abstract available


  31. LIEM KS, Chi H, Fung S, Wong DK, et al
    Early virologic relapse predicts ALT flares after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B.
    J Viral Hepat. 2022 Sep 1. doi: 10.1111/jvh.13742.
    PubMed     Abstract available


    August 2022
  32. SAMALA N, Wang RY, Auh S, Kara Balla A, et al
    Hepatitis E Prevalence and Infection in Solid-Organ Transplant Recipients in the United States.
    J Viral Hepat. 2022 Aug 29. doi: 10.1111/jvh.13739.
    PubMed     Abstract available


  33. YOUNOSSI ZM, Yu ML, El-Kassas M, Esmat G, et al
    Severe Impairment of Patient-Reported Outcomes in Patients with Chronic Hepatitis C Virus Infection Seen in Real-World Practices Across the World: Data from the Global Liver Registry.
    J Viral Hepat. 2022 Aug 29. doi: 10.1111/jvh.13741.
    PubMed     Abstract available


  34. YAMADA R, Morikawa K, Hotta K, Iwami D, et al
    Incidence of post-transplant hepatitis B virus reactivation with the use of kidneys from donors with resolved hepatitis B virus infection.
    J Viral Hepat. 2022 Aug 29. doi: 10.1111/jvh.13740.
    PubMed     Abstract available


  35. MARTIN M, Roth PJ, Niu J, Pericot-Valverde I, et al
    Changes in Alcohol Use during Hepatitis C Treatment in Persons Who Inject Drugs.
    J Viral Hepat. 2022 Aug 23. doi: 10.1111/jvh.13737.
    PubMed     Abstract available


  36. BARRANCO MA, Rosenberg ES, Flanigan C, Shufelt S, et al
    A cross-sectional study of Hepatitis C prevalence and correlates among persons who inject drugs in rural and non-rural communities.
    J Viral Hepat. 2022 Aug 4. doi: 10.1111/jvh.13735.
    PubMed     Abstract available


  37. JIN D, Brener L, Treloar C
    Trust in healthcare providers among Chinese immigrants living with hepatitis B virus in Australia: A qualitative study.
    J Viral Hepat. 2022 Aug 3. doi: 10.1111/jvh.13736.
    PubMed     Abstract available


  38. XU L, Li X, Lu L, Liu X, et al
    HBV pgRNA profiles in Chinese HIV/HBV coinfected patients under pre- and posttreatment: a multicentre observational cohort study.
    J Viral Hepat. 2022;29:616-626.
    PubMed     Abstract available


    July 2022
  39. DENG X, Guo X, Gu H, Wang D, et al
    Anti-HBc-nonreactive occult hepatitis B infections with HBV genotypes B and C in vaccinated immunocompetent adults.
    J Viral Hepat. 2022 Jul 25. doi: 10.1111/jvh.13733.
    PubMed     Abstract available


  40. GAO N, Yu H, Zhang J, Mo Z, et al
    Role of Hepatitis B Surface Antibody in Seroreversion of Hepatitis B Surface Antigen in Patients Achieving Hepatitis B Surface Antigen Loss with Pegylated Interferon-Based Therapy.
    J Viral Hepat. 2022 Jul 24. doi: 10.1111/jvh.13734.
    PubMed     Abstract available


  41. MUTIMER D, Elsharkawy A, Hathorn E, Arunkumar S, et al
    Hepatitis B e antigen and e antibody in a multi-ethnic cohort of adult chronic hepatitis B virus patients followed at a single liver unit for a period of 20 years.
    J Viral Hepat. 2022 Jul 6. doi: 10.1111/jvh.13731.
    PubMed     Abstract available


  42. WANG H, Tong J, Xu X, Chen J, et al
    Reversibility of acute-on-chronic liver failure syndrome in hepatitis B virus-infected patients with and without prior decompensation.
    J Viral Hepat. 2022 Jul 6. doi: 10.1111/jvh.13732.
    PubMed     Abstract available


  43. KUMADA T, Toyoda H, Yasuda S, Ito T, et al
    Original article Factors linked to hepatocellular carcinoma development beyond 10 years after viral eradication in patients with hepatitis C virus.
    J Viral Hepat. 2022 Jul 5. doi: 10.1111/jvh.13728.
    PubMed     Abstract available


  44. PAPATHEODORIDI M, Papachristou E, Moschidis Z, Hadziyannis E, et al
    Significance of serum HBV RNA in non-cirrhotic HBeAg-negative chronic hepatitis B patients who discontinue effective antiviral therapy.
    J Viral Hepat. 2022 Jul 5. doi: 10.1111/jvh.13729.
    PubMed     Abstract available


  45. FORD JS, Hollywood E, Steuble B, Meng Z, et al
    Risk Factors for Hepatitis C Virus Infection at a Large Urban Emergency Department.
    J Viral Hepat. 2022 Jul 5. doi: 10.1111/jvh.13730.
    PubMed     Abstract available


    June 2022
  46. FACTOR SH, Fierer DS
    Can Treatment, Without Prevention, Eliminate Hepatitis C Among Men Who Have Sex With Men?
    J Viral Hepat. 2022 Jun 24. doi: 10.1111/jvh.13726.
    PubMed    


  47. SHATA MTM, Hetta HF, Sharma Y, Sherman KE, et al
    Viral Hepatitis in Pregnancy.
    J Viral Hepat. 2022 Jun 24. doi: 10.1111/jvh.13725.
    PubMed     Abstract available


  48. TAYE BW, Valery PC, Clark PJ
    Targeted antiviral treatment of hepatitis B virus in culturally and linguistically diverse populations to achieve elimination targets in Australia.
    J Viral Hepat. 2022 Jun 24. doi: 10.1111/jvh.13727.
    PubMed     Abstract available


  49. XU JH, Fan YN, Yu YY, Si CW, et al
    240-week Entecavir maleate treatment in Chinese chronic hepatitis B predominantly genotype B or C.
    J Viral Hepat. 2022 Jun 23. doi: 10.1111/jvh.13724.
    PubMed     Abstract available


  50. TRAEGER MW, van Santen DK, Sacks-Davis R, Asselin J, et al
    Impact of COVID-19 lockdown restrictions on hepatitis C testing in Australian primary care services providing care for people who inject drugs.
    J Viral Hepat. 2022 Jun 20. doi: 10.1111/jvh.13723.
    PubMed     Abstract available


  51. YAO N, Wang J, Wu Y, Zhu Y, et al
    Frequent alanine aminotransferase flares and promising antiviral therapy efficacy during the preschool age: an opportunity to achieve HBsAg loss in children with mother-to-child transmitted hepatitis B.
    J Viral Hepat. 2022 Jun 20. doi: 10.1111/jvh.13720.
    PubMed     Abstract available


  52. LIM J, Lee JB, An J, Song GW, et al
    Extrahepatic carcinogenicity of oral nucleos(t)ide analogues in chronic hepatitis B carriers: A 35,000-Korean outcome study.
    J Viral Hepat. 2022 Jun 19. doi: 10.1111/jvh.13721.
    PubMed     Abstract available


  53. CHU JH, Huang Y, Xie DY, Deng H, et al
    Real-world study on HBsAg loss of combination therapy in HBeAg-negative chronic hepatitis B patients.
    J Viral Hepat. 2022 Jun 19. doi: 10.1111/jvh.13722.
    PubMed     Abstract available


  54. RIOS-HINCAPIE CY, Murad-Rivera R, Tohme RA, Ropero AM, et al
    Progress towards the elimination of hepatitis B in children in Colombia: a novel two-phase study approach.
    J Viral Hepat. 2022 Jun 16. doi: 10.1111/jvh.13719.
    PubMed     Abstract available


  55. SHIHA G, Soliman R, Mikhail NNH, Carrat F, et al
    International Multicenter Validation of GES score for HCC risk stratification in chronic hepatitis C patients.
    J Viral Hepat. 2022 Jun 3. doi: 10.1111/jvh.13717.
    PubMed     Abstract available


  56. EVON DM, Dong M, Reeve BB, Peter J, et al
    Sustainable and Equivalent Improvements in Symptoms and Functional Well-Being Following Viral Cure from Ledipasvir/Sofosbuvir versus Elbasvir/Grazoprevir for Chronic Hepatitis C Infection: Findings from the randomized PRIORITIZE trial.
    J Viral Hepat. 2022 Jun 3. doi: 10.1111/jvh.13716.
    PubMed     Abstract available


  57. HSU WF, Lai HC, Chuang PH, Su WP, et al
    Posttreatment nonalcoholic fatty liver disease fibrosis scores for predicting liver-related complications in patients with chronic hepatitis C receiving direct-acting antiviral agents.
    J Viral Hepat. 2022 Jun 3. doi: 10.1111/jvh.13715.
    PubMed     Abstract available


  58. ROBINS A, Dolman G, Williams S, Gelson W, et al
    Hepatitis E Case Series. A UK Experience.
    J Viral Hepat. 2022 Jun 2. doi: 10.1111/jvh.13714.
    PubMed     Abstract available


    May 2022
  59. MARKAKIS GE, Papatheodoridis GV, Cholongitas E
    Epidemiology and treatment of hepatitis E in the liver transplantation setting: A literature review.
    J Viral Hepat. 2022 May 29. doi: 10.1111/jvh.13709.
    PubMed     Abstract available


  60. ASKAR S, Jelley R, McQue K, Allsop C, et al
    Determining the frequency and characteristics of Hepatitis C reinfections in North East England.
    J Viral Hepat. 2022 May 29. doi: 10.1111/jvh.13707.
    PubMed     Abstract available


  61. RAMOS-RINCON JM, Pinargote-Celorio H, de Mendoza C, Ramos-Belinchon C, et al
    Hepatitis C Hospitalizations in Spain and Impact of New Curative Antiviral Therapies.
    J Viral Hepat. 2022 May 29. doi: 10.1111/jvh.13708.
    PubMed     Abstract available


  62. BOLLERUP S, Hallager S, Engsig F, Mocroft A, et al
    Mortality and cause of death in persons with chronic hepatitis B virus infection versus healthy persons from the general population in Denmark.
    J Viral Hepat. 2022 May 27. doi: 10.1111/jvh.13713.
    PubMed     Abstract available


  63. CHEN L, Zhu L, Lu X, Ming X, et al
    TRPM2 regulates autophagy to participate in hepatitis B virus replication.
    J Viral Hepat. 2022 May 27. doi: 10.1111/jvh.13710.
    PubMed     Abstract available


  64. EYMIEUX S, Hourioux C, Marlet J, Moreau A, et al
    A morphometric analysis of hepatitis B subviral particles shows no correlation of filament proportion and length with clinical stage and genotype.
    J Viral Hepat. 2022 May 27. doi: 10.1111/jvh.13712.
    PubMed     Abstract available


  65. MARLEY G, Seto WK, Yan W, Chan P, et al
    What facilitates hepatitis B and hepatitis C testing and the role of stigma among primary care patients in China?
    J Viral Hepat. 2022 May 27. doi: 10.1111/jvh.13711.
    PubMed     Abstract available


  66. PRINSENBERG T, Schinkel J, Zantkuijl P, Davidovich U, et al
    Internet-guided HCV-RNA testing: A promising tool to achieve hepatitis C micro-elimination among men who have sex with men.
    J Viral Hepat. 2022 May 18. doi: 10.1111/jvh.13706.
    PubMed     Abstract available


  67. CARSON JM, Hajarizadeh B, Hanson J, O'Beirne J, et al
    Retreatment for hepatitis C virus direct acting antiviral therapy virological failure in primary and tertiary settings: the REACH-C cohort.
    J Viral Hepat. 2022 May 18. doi: 10.1111/jvh.13705.
    PubMed     Abstract available


  68. ZHENG K, Xia T, Liu N, Xia X, et al
    MicroRNA-206 inhibits HCV proliferation through depressing ACC1 lipid synthesis signaling pathway.
    J Viral Hepat. 2022 May 18. doi: 10.1111/jvh.13703.
    PubMed     Abstract available


  69. MASLAC O, Wagner J, Sozzi V, Mason H, et al
    Secreted Hepatitis B virus splice variants differ by HBV genotype and across phases of chronic hepatitis B infection.
    J Viral Hepat. 2022 May 18. doi: 10.1111/jvh.13702.
    PubMed     Abstract available


  70. BEER L, Inglis S, Malaguti A, Byrne C, et al
    Randomised Clinical Trial: Direct-acting antivirals as treatment for hepatitis C in people who inject drugs: delivered in needle and syringe programs via directly observed therapy versus fortnightly collection.
    J Viral Hepat. 2022 May 18. doi: 10.1111/jvh.13701.
    PubMed     Abstract available


  71. ZHOU G, Chen C, Han G, Jiang H, et al
    Relationship between different hepatitis B virus infection status and gestational diabetes mellitus prevalence among pregnant women with chronic HBV infection: a retrospective study.
    J Viral Hepat. 2022 May 18. doi: 10.1111/jvh.13700.
    PubMed     Abstract available


  72. XU Y, Qi W, Wang X, Zhang Y, et al
    Signal transducer and activator of transcription 3 cooperates with androgen receptor/cell cycle-related kinase signalling pathway in the progression of hepatitis B virus infection and gender differences.
    J Viral Hepat. 2022 May 14. doi: 10.1111/jvh.13699.
    PubMed     Abstract available


  73. VARGAS-ACCARINO E, Martinez-Camprecios J, Dominguez-Hernandez R, Rando-Segura A, et al
    Cost-effectiveness analysis of an active search to retrieve HCV patients lost to follow-up (RELINK-C strategy) and the impact of COVID-19.
    J Viral Hepat. 2022 May 12. doi: 10.1111/jvh.13686.
    PubMed     Abstract available


  74. MASHIBA T, Joko K, Kurosaki M, Ochi H, et al
    Efficacy of hepatitis C virus eradication after curative treatment for hepatocellular carcinoma in patients with advanced hepatocellular carcinoma and decreased hepatic functional reserve: A nationwide, multicentre study by the Japanese Red Cross Live
    J Viral Hepat. 2022 May 12. doi: 10.1111/jvh.13684.
    PubMed     Abstract available


  75. JONES AT, Briones C, Tran T, Moreno-Walton L, et al
    Closing the hepatitis C treatment gap: United States strategies to improve retention in care.
    J Viral Hepat. 2022 May 12. doi: 10.1111/jvh.13685.
    PubMed     Abstract available


  76. HEALY K, Freij U, Ellerstad M, Aulin LBS, et al
    Evaluating the prevalence of Hepatitis E virus infection in a large cohort of European blood donors, 2015-2018.
    J Viral Hepat. 2022 May 2. doi: 10.1111/jvh.13682.
    PubMed     Abstract available


  77. KUWANO A, Yada M, Nagasawa S, Tanaka K, et al
    Hepatitis C virus eradication ameliorates the prognosis of advanced hepatocellular carcinoma treated with sorafenib.
    J Viral Hepat. 2022 May 2. doi: 10.1111/jvh.13681.
    PubMed     Abstract available


    March 2022
  78. LEE J, Ahn SB, Yim SY, An J, et al
    Efficacy and Safety of Direct-Acting Antiviral Therapy for Hepatitis C Virus in Elderly Patients (>/= 65 years old): A Systematic Review and Meta-Analysis.
    J Viral Hepat. 2022 Mar 31. doi: 10.1111/jvh.13679.
    PubMed     Abstract available


  79. TERGAST TL, Blach S, Tacke F, Berg T, et al
    Updated epidemiology of hepatitis C virus infections and implications for hepatitis C virus elimination in Germany.
    J Viral Hepat. 2022 Mar 31. doi: 10.1111/jvh.13680.
    PubMed     Abstract available


  80. HASSAN A, Agustin HGS, Burke L, Kofron R, et al
    Low Incidence and Prevalence of Hepatitis C in Two Cohorts of HIV Pre-Exposure Prophylaxis Adherence Interventions in Men Who Have Sex with Men in Southern California.
    J Viral Hepat. 2022 Mar 31. doi: 10.1111/jvh.13678.
    PubMed     Abstract available


  81. WARD E, Carlisle N, Williams E, Heath SL, et al
    Prevalence of Hepatitis C in Sexual Assault Survivors Presenting to a SANE Clinic: A Descriptive Analysis.
    J Viral Hepat. 2022 Mar 31. doi: 10.1111/jvh.13675.
    PubMed     Abstract available


  82. LIU R, Li M, Lu Y, Zhang L, et al
    Hepatitis B core-related antigen serum levels are associated with significant liver fibrosis in treatment-naive chronic HBV infection patients.
    J Viral Hepat. 2022 Mar 31. doi: 10.1111/jvh.13674.
    PubMed     Abstract available


  83. NEBBIA G, Ruf M, Hunter L, Balasegaram S, et al
    The VirA+EmiC project - Evaluating real-world effectiveness and sustainability of integrated routine opportunistic hepatitis B and C testing in a large urban emergency department.
    J Viral Hepat. 2022 Mar 31. doi: 10.1111/jvh.13676.
    PubMed     Abstract available


  84. KRARUP HB, Rex KF, Andersen S
    Mortality in Greenlanders with chronic hepatitis B virus infection.
    J Viral Hepat. 2022 Mar 31. doi: 10.1111/jvh.13673.
    PubMed     Abstract available


  85. OZGA JE, Syvertsen JL, Pollini RA
    Hepatitis C Antibody Prevalence, Correlates, and Barriers to Care among People Who Inject Drugs in Central California.
    J Viral Hepat. 2022 Mar 31. doi: 10.1111/jvh.13677.
    PubMed     Abstract available


  86. KRINGS A, Schmidt D, Meixenberger K, Bannert N, et al
    Decreasing prevalence and stagnating incidence of Hepatitis C-coinfection among a cohort of HIV-1-positive patients, with a majority of men who have sex with men, in Germany, 1996-2019.
    J Viral Hepat. 2022 Mar 18. doi: 10.1111/jvh.13670.
    PubMed     Abstract available


  87. MA Z, Qin Y, Jia Y, Yiran X, et al
    Thyroid dysfunction incidence and risk factors in Chinese chronic hepatitis B patients treated with pegylated interferon alpha: a long-term follow-up study.
    J Viral Hepat. 2022 Mar 16. doi: 10.1111/jvh.13667.
    PubMed     Abstract available


  88. MORGAN JR, Marsh E, Savinkina A, Shilton S, et al
    Determining the lower limit of detection required for HCV viral load assay for test of cure following direct-acting antiviral based treatment regimens: evidence from a global dataset.
    J Viral Hepat. 2022 Mar 12. doi: 10.1111/jvh.13672.
    PubMed     Abstract available


  89. VERACRUZ N, Gish RG, Cheung R, Chitnis AS, et al
    Global incidence and mortality of hepatitis B and hepatitis C acute infections, cirrhosis and hepatocellular carcinoma from 2010 to 2019.
    J Viral Hepat. 2022 Mar 11. doi: 10.1111/jvh.13663.
    PubMed     Abstract available


  90. HOWELL J, Traeger MW, Williams B, Layton C, et al
    The impact of point-of-care hepatitis C testing in needle and syringe exchange programs on linkage to care and treatment uptake among people who inject drugs: An Australian pilot study.
    J Viral Hepat. 2022 Mar 11. doi: 10.1111/jvh.13664.
    PubMed     Abstract available


  91. CHROMY D, Bauer DJM, Simbrunner B, Jachs M, et al
    'Viennese epidemic' of acute HCV in the era of direct-acting antivirals.
    J Viral Hepat. 2022 Mar 11. doi: 10.1111/jvh.13665.
    PubMed     Abstract available


  92. EL EKIABY M, Tanaka J, van Drimmelen H, Allain JP, et al
    Infectivity of hepatitis B virus (HBV) surface antigen (HBsAg) positive plasma with undetectable HBV-DNA: Can HBsAg screening be discontinued in Egyptian blood donors?
    J Viral Hepat. 2022 Mar 11. doi: 10.1111/jvh.13666.
    PubMed     Abstract available


  93. AKIYAMA MJ, Riback L, Nyakowa M, Musyoki H, et al
    Hepatitis C Treatment Outcomes Among People Who Inject Drugs Accessing Harm Reduction Settings in Kenya.
    J Viral Hepat. 2022 Mar 11. doi: 10.1111/jvh.13662.
    PubMed     Abstract available


  94. ZENG X, Ayibaota B, Tuerhanbayi B, Zheng M, et al
    The altered HLA-DQ expression in peripheral blood T cells of chronic hepatitis B patients characterizes the function of T cells.
    J Viral Hepat. 2022 Mar 10. doi: 10.1111/jvh.13669.
    PubMed     Abstract available


  95. WANG Y, Liao H, Deng Z, Liu Y, et al
    Serum HBV RNA predicts HBeAg clearance and seroconversion in patients with chronic hepatitis B treated with nucleos(t)ide analogues.
    J Viral Hepat. 2022 Mar 10. doi: 10.1111/jvh.13671.
    PubMed     Abstract available


  96. KAUR H, Dhiman RK, Kulkarni AV, Premkumar M, et al
    Improvement of Chronic HCV infection related Depression, Anxiety, and Neurocognitive performance in persons achieving SVR-12: a Real-world Cohort Study.
    J Viral Hepat. 2022 Mar 10. doi: 10.1111/jvh.13668.
    PubMed     Abstract available


  97. NEPHEW LD, Wang Y, Mohamed K, Nichols D, et al
    Removal of Medicaid Restrictions were Associated with Increased Hepatitis-C Virus Treatment Rates, But Disparities Persist.
    J Viral Hepat. 2022 Mar 7. doi: 10.1111/jvh.13661.
    PubMed     Abstract available


  98. JI DZ, Pang XY, Shen DT, Liu SN, et al
    Global prevalence of occult Hepatitis B: a systematic review and meta-analysis.
    J Viral Hepat. 2022 Mar 7. doi: 10.1111/jvh.13660.
    PubMed     Abstract available


  99. TAN Q, Chen J, Gao G, Yizhang, et al
    Adenovirus vector encoding TPPII ignites HBV-specific CTL response by activating autophagy in CD8+ T cell.
    J Viral Hepat. 2022;29:178-188.
    PubMed     Abstract available


    February 2022
  100. HOSSEINI-HOOSHYAR S, Alavi M, Martinello M, Valerio H, et al
    Evaluation of the hepatitis C cascade of care among people living with HIV in New South Wales, Australia: A data linkage study.
    J Viral Hepat. 2022 Feb 17. doi: 10.1111/jvh.13658.
    PubMed     Abstract available


  101. WU G, Zhou A, Kwon S
    Integrating Hepatitis C Virus Screening of Baby Boomers at a Community Hospital Emergency Department.
    J Viral Hepat. 2022 Feb 13. doi: 10.1111/jvh.13654.
    PubMed     Abstract available


  102. CHON YE, Park SY, Kim SU, Hong HP, et al
    Long-term renal safety between patients with chronic hepatitis B receiving tenofovir vs. entecavir therapy: A multicenter study.
    J Viral Hepat. 2022 Feb 13. doi: 10.1111/jvh.13656.
    PubMed     Abstract available


  103. FENG R, Liu Y, Zhu XL, Zhai WY, et al
    Recombinant human thrombopoietin increases platelet count in severe thrombocytopenic patients with hepatitis B related cirrhosis: multi-center real-world observational study.
    J Viral Hepat. 2022 Feb 13. doi: 10.1111/jvh.13655.
    PubMed     Abstract available


  104. YARDENI D, Heller T, Koh C
    Chronic hepatitis D - What is changing?
    J Viral Hepat. 2022 Feb 4. doi: 10.1111/jvh.13651.
    PubMed     Abstract available


  105. WU A, Liu Y
    Use of HBV DNA and liver stiffness in predicting clinical events in patients with chronic hepatitis B.
    J Viral Hepat. 2022 Feb 4. doi: 10.1111/jvh.13653.
    PubMed    


  106. KHERA T, Madsen LW, Du Y, Lillevang ST, et al
    Soluble inflammatory mediators identify HCV patients who may be cured with four weeks of antiviral treatment.
    J Viral Hepat. 2022 Feb 4. doi: 10.1111/jvh.13652.
    PubMed     Abstract available


    January 2022
  107. HUA R, Kong F, Wen X, Xiong Q, et al
    Efficacy and safety of alfosbuvir plus daclatasvir in Chinese patients with hepatitis C virus genotypes 1, 2, 3, and 6 infection - an open-label, phase 2 study.
    J Viral Hepat. 2022 Jan 26. doi: 10.1111/jvh.13650.
    PubMed     Abstract available


  108. WU S, Yuan H, Fan H, Xu Y, et al
    Evolutionary characteristics and immune mutation of hepatitis C virus genotype 1b among intravenous drug users in mainland, China.
    J Viral Hepat. 2022 Jan 25. doi: 10.1111/jvh.13647.
    PubMed     Abstract available


  109. LU Z, Zhou Y, Yan R, Deng X, et al
    Post vaccination serologic testing of infants born to hepatitis B surface antigen positive mothers is more Cost-effective in Zhejiang Province,China: A Markov chain analysis.
    J Viral Hepat. 2022 Jan 25. doi: 10.1111/jvh.13649.
    PubMed     Abstract available


  110. CHOI WM, Lim YS
    Use of HBV DNA and liver stiffness in predicting clinical events in patients with chronic hepatitis B.
    J Viral Hepat. 2022 Jan 25. doi: 10.1111/jvh.13648.
    PubMed    


  111. STOCKDALE AJ, Kreuels B, Shawa IT, Meiring JE, et al
    A clinical and molecular epidemiological survey of hepatitis C in Blantyre, Malawi suggests an historic mechanism of transmission.
    J Viral Hepat. 2022 Jan 25. doi: 10.1111/jvh.13646.
    PubMed     Abstract available


  112. WASUWANICH P, Striley CW, Kamili S, Teshale EH, et al
    Hepatitis D-Associated Hospitalizations in the United States: 2010-2018.
    J Viral Hepat. 2022 Jan 25. doi: 10.1111/jvh.13645.
    PubMed     Abstract available


  113. ZHANG Y, Yang M, Huang X, Yang H, et al
    Comments on: The role of caesarean section and nonbreastfeeding in preventing mother-to-child transmission of hepatitis B virus in HBsAg-and HBeAg-positive mothers: results from a prospective cohort study and a meta-analysis.
    J Viral Hepat. 2022 Jan 8. doi: 10.1111/jvh.13641.
    PubMed    


  114. PAN YC, Jia ZF, Wu YH, Lv HY, et al
    Response to comments on: The role of caesarean section and nonbreastfeeding in preventing mother-to-child transmission of hepatitis B virus in HBsAg-and HBeAg-positive mothers: results from a prospective cohort study and a meta-analysis.
    J Viral Hepat. 2022 Jan 6. doi: 10.1111/jvh.13642.
    PubMed    


  115. IKENAGA H, Uchida-Kobayashi S, Tamori A, Odagiri N, et al
    Direct-acting antivirals reduce the risk of tumour progression of hepatocellular carcinoma after curative treatment.
    J Viral Hepat. 2022;29:52-59.
    PubMed     Abstract available


  116. ELZEFZAFY W, Soliman R, Saleh L, Mahmoud S, et al
    Seroprevalence and epidemiological characteristics of HDV infection among HBV patients in the Nile Delta, Egypt.
    J Viral Hepat. 2022;29:87-90.
    PubMed     Abstract available


    December 2021
  117. ZHOU Y, Li J, Gordon SC, Trudeau S, et al
    Laboratory monitoring and antiviral treatment for chronic hepatitis B among routine care patients in the United States.
    J Viral Hepat. 2021 Dec 14. doi: 10.1111/jvh.13639.
    PubMed     Abstract available


  118. WANG XD, Pan CW, Zhou GY, Gao F, et al
    Effect of liver steatosis on liver stiffness measurement in chronic hepatitis B patients with normal serum alanine aminotransferase levels: A multicentre cohort study.
    J Viral Hepat. 2021 Dec 13. doi: 10.1111/jvh.13640.
    PubMed     Abstract available


  119. CHOI HSJ, Sonneveld MJ, Farag MS, Brouwer WP, et al
    Effects of on-treatment ALT flares on serum HBsAg and HBV RNA in patients with chronic HBV infection.
    J Viral Hepat. 2021;28:1729-1737.
    PubMed     Abstract available


  120. DJORDJEVIC F, Ryan K, Gunn J, Brener L, et al
    Health service utilization and experiences of stigma amongst people who inject drugs in Melbourne, Australia.
    J Viral Hepat. 2021;28:1738-1743.
    PubMed     Abstract available


    November 2021
  121. MANDEL E, Peci A, Cronin K, Capraru CI, et al
    The Impact of the First, Second, and Third Waves of COVID-19 on Hepatitis B and C Testing in Ontario, Canada.
    J Viral Hepat. 2021 Nov 25. doi: 10.1111/jvh.13637.
    PubMed     Abstract available


  122. GIADANS CG, Rios DA, Ameigeiras B, Haddad L, et al
    Intrahepatic immune infiltrate in chronic hepatitis B and chronic hepatitis C: Similar but not the same.
    J Viral Hepat. 2021 Nov 25. doi: 10.1111/jvh.13635.
    PubMed     Abstract available


  123. LEMOINE M, Ndow G, Shimakawa Y
    Improving disease knowledge is critical to eliminate hepatitis B.
    J Viral Hepat. 2021 Nov 22. doi: 10.1111/jvh.13633.
    PubMed     Abstract available


  124. FORNS X, Colom J, Garcia-Retortillo M, Quer JC, et al
    Point-of-care hepatitis C testing and treatment strategy for people attending harm reduction and addiction centres for hepatitis C elimination.
    J Viral Hepat. 2021 Nov 22. doi: 10.1111/jvh.13634.
    PubMed     Abstract available


  125. MOHAMED EI, El-Ghnam SM, Bayoumi AM, Abdel-Mageed SM, et al
    Electronic Nose versus Quadrupole Mass Spectrometry for Identifying Viral Hepatitis C Patients.
    J Viral Hepat. 2021 Nov 12. doi: 10.1111/jvh.13630.
    PubMed     Abstract available


  126. CHIDWICK K, Myton R, Rodgers A, Jun M, et al
    A cluster randomized controlled trial of a MedicineInsight Educational Quality Improvement Programme to improve the diagnosis and treatment of chronic hepatitis C in general practice (the EQUIP-HEPC trial).
    J Viral Hepat. 2021 Nov 11. doi: 10.1111/jvh.13629.
    PubMed     Abstract available


  127. JO AJ, Choi WM, Kim HJ, Choi SH, et al
    A risk scoring system to predict clinical events in chronic hepatitis B virus infection: A nationwide cohort study.
    J Viral Hepat. 2021 Nov 11. doi: 10.1111/jvh.13631.
    PubMed     Abstract available


  128. CHANG HL, Wen WH, Lee CN, Chiu YE, et al
    Kinetics of Hepatitis B Surface Antigen in Pregnant Women with and without Tenofovir Disoproxil Fumarate.
    J Viral Hepat. 2021 Nov 1. doi: 10.1111/jvh.13628.
    PubMed     Abstract available


  129. GANE E, de Ledinghen V, Dylla DE, Rizzardini G, et al
    Positive predictive value of sustained virologic response 4 weeks posttreatment for achieving sustained virologic response 12 weeks posttreatment in patients receiving glecaprevir/pibrentasvir in Phase 2 and 3 clinical trials.
    J Viral Hepat. 2021;28:1635-1642.
    PubMed     Abstract available


    October 2021
  130. JUGNARAIN DV, Halford R, Smith S, Hickman M, et al
    Role of peer support in a hepatitis C elimination program.
    J Viral Hepat. 2021 Oct 18. doi: 10.1111/jvh.13626.
    PubMed     Abstract available


  131. KUWANO A, Yada M, Nagasawa S, Tanaka K, et al
    Serum alpha-fetoprotein level at treatment completion is a useful predictor of hepatocellular carcinoma occurrence more than one year after hepatitis C virus eradication by direct-acting antiviral treatment.
    J Viral Hepat. 2021 Oct 18. doi: 10.1111/jvh.13625.
    PubMed     Abstract available


  132. RAMIREZ MENA A, Tine JM, Fortes L, Ndiaye O, et al
    Hepatitis B screening practices and viral control among persons living with HIV in urban Senegal.
    J Viral Hepat. 2021 Oct 5. doi: 10.1111/jvh.13615.
    PubMed     Abstract available


  133. ZHOU Y, Lu Z, He H, Yan R, et al
    Influencing factors and necessity of post-vaccination serologic testing follow-up for HBsAg-positive mothers and their infants: A 5-year prospective study in Zhejiang Province, China (2016-2020).
    J Viral Hepat. 2021;28:1413-1421.
    PubMed     Abstract available


    September 2021
  134. NISHIGUCHI J, McNamara A, Surlyn CS, Eagen KV, et al
    Efficacy of an eConsult Service to Cure Hepatitis C in Primary Care.
    J Viral Hepat. 2021 Sep 29. doi: 10.1111/jvh.13616.
    PubMed     Abstract available


  135. COPPOLA C, Masarone M, Bartoli M, Staiano L, et al
    Associated screening for HCV and SARS-Cov2 infection in an urban area of Southern Italy: a cohort study.
    J Viral Hepat. 2021 Sep 29. doi: 10.1111/jvh.13623.
    PubMed     Abstract available


  136. STROFFOLINI T, Morisco F, Ferrigno L, Pontillo G, et al
    Acute Delta Hepatitis in Italy spanning three decades (1991-2019): evidence for the effectiveness of the hepatitis B vaccination campaign.
    J Viral Hepat. 2021 Sep 29. doi: 10.1111/jvh.13620.
    PubMed     Abstract available


  137. HARNEY BL, Brereton R, Whitton B, Pietrzak D, et al
    Letter in response: Psychiatrists can treat hepatitis C.
    J Viral Hepat. 2021 Sep 28. doi: 10.1111/jvh.13619.
    PubMed     Abstract available


  138. RODER C, Nguyen P, Harvey C, Wardrop M, et al
    Psychiatrists can treat hepatitis C.
    J Viral Hepat. 2021 Sep 28. doi: 10.1111/jvh.13622.
    PubMed     Abstract available


  139. ROSATO V, Ascione A, Nevola R, Fracanzani AL, et al
    Factors affecting long-term changes of liver stiffness in direct-acting anti-hepatitis C virus therapy: a multicenter prospective study.
    J Viral Hepat. 2021 Sep 28. doi: 10.1111/jvh.13617.
    PubMed     Abstract available


  140. SOHN W, Chang Y, Cho YK, Hong YS, et al
    Liver fibrosis scores and risk of liver-related mortality in young adults with chronic hepatitis B: A cohort study.
    J Viral Hepat. 2021 Sep 28. doi: 10.1111/jvh.13618.
    PubMed     Abstract available


  141. CAVEN M, Baiano CX, Robinson EM, Stephens B, et al
    Hepatitis C reinfection by treatment pathway among people who inject drugs in Tayside, Scotland.
    J Viral Hepat. 2021 Sep 15. doi: 10.1111/jvh.13614.
    PubMed     Abstract available


  142. KOUTSIANAS C, Hadziyannis E, Thomas K, Deutsch M, et al
    Kinetics of quantitative hepatitis B surface antigen in patients with rheumatic disease and chronic hepatitis B receiving biologic agents.
    J Viral Hepat. 2021 Sep 8. doi: 10.1111/jvh.13610.
    PubMed     Abstract available


  143. MARCELLIN F, Di Beo V, Esterle L, Abgrall S, et al
    Post-HCV cure self-reported changes in physical activity, eating behaviors, and fatigue in people living with HIV (ANRS CO13 HEPAVIH).
    J Viral Hepat. 2021 Sep 2. doi: 10.1111/jvh.13605.
    PubMed     Abstract available


  144. DOUMBIA M, Sevede D, Kouakou V, Kouakou C, et al
    Viral and bacterial factors of mother-to-child transmission of hepatitis B virus.
    J Viral Hepat. 2021 Sep 1. doi: 10.1111/jvh.13607.
    PubMed     Abstract available


  145. HAMDIUI N, van Steenbergen J, Rocha LEC, Meiberg A, et al
    Hepatitis B screening among immigrants: how to successfully reach the Moroccan community.
    J Viral Hepat. 2021 Sep 1. doi: 10.1111/jvh.13604.
    PubMed     Abstract available


  146. CHEUNG KW, Seto MTY, Tsui PM, So PL, et al
    Knowledge, perception and expectation of management of hepatitis B infection among pregnant hepatitis B carriers in Hong Kong.
    J Viral Hepat. 2021 Sep 1. doi: 10.1111/jvh.13609.
    PubMed     Abstract available


  147. ERKEN R, Andre P, Roy E, Kootstra N, et al
    Farnesoid X receptor agonist for the treatment of chronic hepatitis B; a safety study.
    J Viral Hepat. 2021 Sep 1. doi: 10.1111/jvh.13608.
    PubMed     Abstract available


  148. GARCIA-CEHIC D, Rando A, Rodriguez-Frias F, Gregori J, et al
    Resistance-associated substitutions after sofosbuvir/velpatasvir/voxilaprevir triple therapy failure.
    J Viral Hepat. 2021;28:1319-1324.
    PubMed     Abstract available


    August 2021
  149. TSAI HJ, Chuang YW, Yang SS, Chang YZ, et al
    Evaluating the renal safety of tenofovir disoproxil fumarate in hepatitis B patients without chronic kidney disease.
    J Viral Hepat. 2021 Aug 31. doi: 10.1111/jvh.13603.
    PubMed     Abstract available


  150. WANG L, Zhao J, Liu J, Zhen C, et al
    Long-term benefits of interferon-alpha therapy in children with HBeAg-positive immune-active chronic hepatitis B.
    J Viral Hepat. 2021 Aug 26. doi: 10.1111/jvh.13598.
    PubMed     Abstract available


  151. LEE HW, Cho YY, Lee H, Lee JS, et al
    Effect of tenofovir alafenamide versus tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B.
    J Viral Hepat. 2021 Aug 26. doi: 10.1111/jvh.13601.
    PubMed     Abstract available


  152. CHEN Y, Zhao YL, Hao ZY, Zhang XJ, et al
    Long-term persistence of anti-HAV antibody conferred by a single dose of live-attenuated hepatitis A vaccine: results from 17-year follow-up.
    J Viral Hepat. 2021 Aug 26. doi: 10.1111/jvh.13602.
    PubMed     Abstract available


  153. WONG RJ, Cheung R, Gish RG, Chitnis AS, et al
    Prevalence of Hepatitis E Infection among Adults with Concurrent Chronic Liver Disease.
    J Viral Hepat. 2021 Aug 20. doi: 10.1111/jvh.13597.
    PubMed     Abstract available


  154. CHEN B, Huang H, Pan CQ
    The Role of Gut Microbiota in Hepatitis B Disease Progression and Treatment.
    J Viral Hepat. 2021 Aug 20. doi: 10.1111/jvh.13595.
    PubMed     Abstract available


  155. PALMER AY, Chan K, Gold J, Layton C, et al
    A modelling analysis of financial incentives for hepatitis C testing and treatment uptake delivered through a community-based testing campaign.
    J Viral Hepat. 2021 Aug 20. doi: 10.1111/jvh.13596.
    PubMed     Abstract available


  156. CHANG JW, Lee JS, Lee HW, Kim BK, et al
    No influence of hepatic steatosis on the 3-year outcomes of patients with quiescent chronic hepatitis B.
    J Viral Hepat. 2021 Aug 12. doi: 10.1111/jvh.13594.
    PubMed     Abstract available


  157. BALL LE, Agana B, Comte-Walters S, Rockey DC, et al
    Hepatitis C Virus Treatment with Direct Acting Antivirals Induces Rapid Changes in the Hepatic Proteome.
    J Viral Hepat. 2021 Aug 11. doi: 10.1111/jvh.13593.
    PubMed     Abstract available


  158. FREELAND C, Racho R, Kamischke M, Moraras K, et al
    Cure everyone and vaccinate the rest: The patient perspective on future hepatitis B treatment.
    J Viral Hepat. 2021 Aug 7. doi: 10.1111/jvh.13592.
    PubMed     Abstract available


  159. LEE WM, King WC, Janssen HLA, Ghany MG, et al
    Hepatitis B e Antigen Loss in Adults and Children with Chronic Hepatitis B Living in North America: A Prospective Cohort Study.
    J Viral Hepat. 2021 Aug 6. doi: 10.1111/jvh.13591.
    PubMed     Abstract available


  160. PERIERES L, Protopopescu C, Lo G, Marcellin F, et al
    Sibling status, home birth, tattoos and stitches are risk factors for chronic hepatitis B virus infection in Senegalese children: a cross-sectional survey.
    J Viral Hepat. 2021 Aug 6. doi: 10.1111/jvh.13589.
    PubMed     Abstract available


  161. DJEBALI-TRABELSI A, Marot A, Andre C, Deltenre P, et al
    Large-scale screening is not useful for identifying individuals with hepatitis B or C virus infection: a prospective Swiss study.
    J Viral Hepat. 2021 Aug 3. doi: 10.1111/jvh.13588.
    PubMed     Abstract available


  162. XU C, Bao Y, Zuo J, Li Y, et al
    Maternal chronic hepatitis B virus infection and the risk of preterm birth: a retrospective cohort analysis in Chinese Women.
    J Viral Hepat. 2021 Aug 3. doi: 10.1111/jvh.13585.
    PubMed     Abstract available


  163. KNOP V, Hoppe D, Vermehren J, Troetschler S, et al
    Non-invasive assessment of fibrosis regression and portal hypertension in patients with advanced chronic hepatitis C virus (HCV)-associated liver disease and sustained virologic response (SVR): 3 year follow-up of a prospective longitudinal study.
    J Viral Hepat. 2021 Aug 3. doi: 10.1111/jvh.13587.
    PubMed     Abstract available


  164. HUPPE D, Stoehr A, Buggisch P, Mauss S, et al
    The changing characteristics of patients infected with chronic hepatitis C virus from 2014 to 2019: Real-world data from the German Hepatitis C-Registry (DHC-R).
    J Viral Hepat. 2021 Aug 2. doi: 10.1111/jvh.13586.
    PubMed     Abstract available


    July 2021
  165. SANTOS-LIMA C, Souza-Marques B, Vieira F, Schinoni MI, et al
    Neuropsychological effects of direct-acting antiviral treatment for HCV subjects: a systematic review.
    J Viral Hepat. 2021 Jul 28. doi: 10.1111/jvh.13584.
    PubMed     Abstract available


  166. WANG Y, Zhao Z, Zhang H, Lin Q, et al
    Estimating the transmissibility of hepatitis C: a modelling study in Yichang City, China.
    J Viral Hepat. 2021 Jul 27. doi: 10.1111/jvh.13582.
    PubMed     Abstract available


  167. DEL ROSARIO A, Eldredge JD, Doorley S, Mishra SI, et al
    Hepatitis C Virus Care Cascade in Persons Experiencing Homelessness in the United States in the Era of Direct-Acting Antiviral Agents: A Scoping Review.
    J Viral Hepat. 2021 Jul 27. doi: 10.1111/jvh.13583.
    PubMed     Abstract available


  168. OHKI T, Satov K, Kondo M, Goto E, et al
    Effectiveness of direct acting antiviral agents for hepatitis C virus related recurrent hepatocellular carcinoma patients who had multiple courses of recurrence.
    J Viral Hepat. 2021 Jul 27. doi: 10.1111/jvh.13579.
    PubMed     Abstract available


  169. ZHANG S, Chen Z, Wei J, Chi X, et al
    A model based on clinico-biochemical characteristics and deep learning features from MR images for assessing necroinflammatory activity in chronic hepatitis B.
    J Viral Hepat. 2021 Jul 27. doi: 10.1111/jvh.13578.
    PubMed     Abstract available


  170. YOUSAFZAI MT, Bajis S, Alavi M, Grebely J, et al
    Treatment cascade of care for chronic hepatitis C virus infection globally: Systematic review and meta-analysis.
    J Viral Hepat. 2021 Jul 26. doi: 10.1111/jvh.13574.
    PubMed     Abstract available


  171. HEYWOOD A, Dyda A, Hu W, Saha A, et al
    Seroprevalence of hepatitis B antibodies among international and domestic university students.
    J Viral Hepat. 2021 Jul 26. doi: 10.1111/jvh.13580.
    PubMed     Abstract available


  172. KAMAL H, Fornes R, Simin J, Stal P, et al
    Risk of Hepatocellular Carcinoma in Hepatitis B and D Virus Co-Infected Patients: A Systematic Review and Meta-analysis of Longitudinal studies.
    J Viral Hepat. 2021 Jul 22. doi: 10.1111/jvh.13577.
    PubMed     Abstract available


  173. BISCHOFF J, Mauss S, Lutz T, Cordes C, et al
    Late presentation of chronic hepatitis C patients in the era of direct acting antivirals - Data from the German Hepatitis C-Registry.
    J Viral Hepat. 2021 Jul 21. doi: 10.1111/jvh.13576.
    PubMed     Abstract available


  174. BARDSLEY M, Heinsbroek E, Harris R, Croxford S, et al
    The Impact Of Direct-Acting Antivirals On Hepatitis C Viraemia Among People Who Inject Drugs In England; Real-World Data 2011-2018.
    J Viral Hepat. 2021 Jul 16. doi: 10.1111/jvh.13575.
    PubMed     Abstract available


  175. NA JE, Sinn DH, Lee JH, Jang HJ, et al
    Efficacy of entecavir vs tenofovir in preventing hepatocellular carcinoma in patients with chronic hepatitis B with maintained virologic response.
    J Viral Hepat. 2021 Jul 12. doi: 10.1111/jvh.13572.
    PubMed     Abstract available


  176. VARCHETTA S, Mele D, D'Ambrosio R, Perbellini R, et al
    A new algorithm shows superior ability to discriminate liver fibrosis stages in chronic hepatitis C.
    J Viral Hepat. 2021 Jul 6. doi: 10.1111/jvh.13570.
    PubMed     Abstract available


  177. LI J, Qu L, Sun X, Liu Y, et al
    Peg-interferon alpha add-on Tenofovir disoproxil fumarate achieved more HBsAg loss in HBeAg positive chronic hepatitis B naive patients.
    J Viral Hepat. 2021 Jul 6. doi: 10.1111/jvh.13571.
    PubMed     Abstract available


  178. ERICE A, Varillas-Delgado D, Caballero C
    Prevalence and characteristics of hepatitis C virus infection detected by extended screening of working-age adults in Madrid (Spain).
    J Viral Hepat. 2021 Jul 5. doi: 10.1111/jvh.13564.
    PubMed     Abstract available


  179. KAMALAPIRAT T, Ungtrakul T
    Reply to "Consider more about risk scores for predicting hepatocellular carcinoma in patients with chronic hepatitis B".
    J Viral Hepat. 2021 Jul 5. doi: 10.1111/jvh.13566.
    PubMed     Abstract available


  180. LOU T, Li B, Xiong P, Jin C, et al
    External Validation of Hepatocellular Carcinoma Risk Scores in Patients with Chronic Hepatitis B Virus Infection in China.
    J Viral Hepat. 2021 Jul 4. doi: 10.1111/jvh.13569.
    PubMed     Abstract available


  181. FARSIMADAN M, Riahi SM, Muhammad HM, Emamvirdizadeh A, et al
    The Effects of Hepatitis B Virus Infection on Natural and IVF Pregnancy: A Meta-analysis Study.
    J Viral Hepat. 2021 Jul 3. doi: 10.1111/jvh.13565.
    PubMed     Abstract available


  182. LIU Y
    Consider more about risk scores for predicting hepatocellular carcinoma in patients with chronic hepatitis B.
    J Viral Hepat. 2021 Jul 3. doi: 10.1111/jvh.13568.
    PubMed     Abstract available


  183. LIU Y
    Reply to "Consider more about risk scores for predicting hepatocellular carcinoma in patients with chronic hepatitis B" - a reply.
    J Viral Hepat. 2021 Jul 3. doi: 10.1111/jvh.13567.
    PubMed     Abstract available


  184. MCGUIRE FH, Andre K, Bradsher ML, Harrison D, et al
    Willingness to participate in research among black patients with liver disease: A national cross-sectional study.
    J Viral Hepat. 2021;28:982-993.
    PubMed     Abstract available


    June 2021
  185. GIRALDEZ-GALLEGO A, Rodriguez-Seguel E, Pascasio-Acevedo JM
    Optimal hepatitis B vaccination schedule for cirrhotic patients: a still unanswered question.
    J Viral Hepat. 2021 Jun 29. doi: 10.1111/jvh.13563.
    PubMed     Abstract available


  186. KIM HP, Edwards A, Reeve BB, Golin CE, et al
    Symptoms and Functioning Improve after Chronic Hepatitis C Cure as Assessed by the Memorial Symptom Assessment Scale and PROMIS Measures.
    J Viral Hepat. 2021 Jun 29. doi: 10.1111/jvh.13561.
    PubMed     Abstract available


  187. KUMADA T, Toyoda H, Yasuda S, Tada T, et al
    Long-term outcomes of viral eradication in patients with hepatitis C virus infection and mild hepatic fibrosis.
    J Viral Hepat. 2021 Jun 29. doi: 10.1111/jvh.13562.
    PubMed     Abstract available


  188. YOO S, Lim TS, Lee HW, Kim JK, et al
    Risk assessment of hepatocellular carcinoma and liver-related events using ultrasonography and transient elastography in patients with chronic hepatitis B.
    J Viral Hepat. 2021 Jun 29. doi: 10.1111/jvh.13560.
    PubMed     Abstract available


  189. KANG Q, Xu J, Luo H, Tan N, et al
    Direct antiviral agent treatment leads to rapid and significant fibrosis regression after HCV eradication.
    J Viral Hepat. 2021 Jun 9. doi: 10.1111/jvh.13558.
    PubMed     Abstract available


  190. NISHIDA Y, Imamura M, Yuji T, Morio K, et al
    Serum PreS1 and HBsAg ratio reflects liver fibrosis and predicts the development of hepatocellular carcinoma in chronic hepatitis B patients.
    J Viral Hepat. 2021 Jun 9. doi: 10.1111/jvh.13557.
    PubMed     Abstract available


  191. DONG Y, Li A, Zhu S, Chen W, et al
    Biopsy-proven liver cirrhosis in young children: A 10-year cohort study.
    J Viral Hepat. 2021;28:959-963.
    PubMed     Abstract available


  192. CHENG D, Han B, Zhang W, Wu W, et al
    Clinical effects of NTCP-inhibitor myrcludex B.
    J Viral Hepat. 2021;28:852-858.
    PubMed     Abstract available


    May 2021
  193. WANG S, Fang S, Liu Y
    The 5-year cumulative incidence HCC development and treatment regimen in patients with chronic hepatitis B receiving nucleotide/nucleoside analogue treatment.
    J Viral Hepat. 2021 May 29. doi: 10.1111/jvh.13553.
    PubMed     Abstract available


  194. BROWN C, Siegele M, Wright M, Cook C, et al
    Injecting network structure determines the most efficient strategy to achieve Hepatitis C elimination in people who inject drugs.
    J Viral Hepat. 2021 May 28. doi: 10.1111/jvh.13554.
    PubMed     Abstract available


  195. RODRIGUEZ-TAJES S, Lens S, Forns X
    Reply to: Optimal hepatitis B vaccination schedule for cirrhotic patients: a still unanswered question.
    J Viral Hepat. 2021 May 28. doi: 10.1111/jvh.13555.
    PubMed     Abstract available


  196. ARSLAN F, Franci G, Nastri BM, Pagliano P, et al
    Hepatitis B virus-induced Hepatocarcinogenesis: A Virological and Oncological Perspective.
    J Viral Hepat. 2021 May 18. doi: 10.1111/jvh.13551.
    PubMed     Abstract available


  197. SMITH DA, Bradshaw D, Mbisa J, Manso CF, et al
    Real World SOF/VEL/VOX Retreatment Outcomes and Viral Resistance Analysis for HCV Patients with Prior Failure to DAA Therapy.
    J Viral Hepat. 2021 May 18. doi: 10.1111/jvh.13549.
    PubMed     Abstract available


  198. OHLENDORF V, Schafer A, Christensen S, Heyne R, et al
    Only partial improvement in health-related quality of life after treatment of chronic hepatitis C virus infection with direct acting antivirals in a real-world setting- results from the German Hepatitis C-Registry (DHC-R).
    J Viral Hepat. 2021 May 18. doi: 10.1111/jvh.13546.
    PubMed     Abstract available


  199. DUFFELL E, Cortez-Pinto H, Simonova M, Dalgard O, et al
    Estimating the attributable fraction of cirrhosis and hepatocellular carcinoma due to hepatitis B and C.
    J Viral Hepat. 2021 May 18. doi: 10.1111/jvh.13545.
    PubMed     Abstract available


  200. LIU PC, Chan C, Huang YH, Chen YJ, et al
    Genetic Variants Associated With Serum Alanine Aminotransferase Levels Among Patients With Hepatitis C Virus Infection: A Genome-Wide Association Study.
    J Viral Hepat. 2021 May 18. doi: 10.1111/jvh.13550.
    PubMed     Abstract available


  201. KIM S, Powell J, Naugle J, Ricco M, et al
    Patient-Reported Experiences with Direct Acting Antiviral Therapy in an Integrated Model of Hepatitis C Care in Homeless Shelters.
    J Viral Hepat. 2021 May 18. doi: 10.1111/jvh.13544.
    PubMed     Abstract available


  202. NANA J, Skaare K, Bosson JL, Leroy V, et al
    EASL-ALEH 2015 algorithm for the use of transient elastography in treatment-naive patients with Hepatitis B: an independent validation.
    J Viral Hepat. 2021 May 18. doi: 10.1111/jvh.13548.
    PubMed     Abstract available


  203. MCDONALD SA, Barclay ST, Innes HA, Fraser A, et al
    Uptake of interferon-free DAA therapy among HCV-infected decompensated cirrhosis patients and evidence for decreased mortality.
    J Viral Hepat. 2021 May 18. doi: 10.1111/jvh.13543.
    PubMed     Abstract available


  204. COMBET C, Bhardwaj N, Hedskog C, Podlaha O, et al
    Hepatitis B Virus Genome Diversity in Adolescents: Tenofovir Disoproxil Fumarate Treatment Effect and HBeAg Seroconversion.
    J Viral Hepat. 2021 May 18. doi: 10.1111/jvh.13547.
    PubMed     Abstract available


  205. HUANG PY, Wang JH, Hung CH, Lu SN, et al
    The role of hepatitis B virus core-related antigen in predicting hepatitis B virus relapse after cessation of entecavir in hepatitis B e antigen-negative patients.
    J Viral Hepat. 2021 May 1. doi: 10.1111/jvh.13528.
    PubMed     Abstract available


  206. WOLF JM, Pereira VRZB, Simon D, Lunge VR, et al
    Temporal and geographic spreading of hepatitis B virus genotype A (HBV-A) in Brazil and the Americas.
    J Viral Hepat. 2021 May 1. doi: 10.1111/jvh.13527.
    PubMed     Abstract available


  207. COWAN E, Hardardt J, Brandspiegel S, Eiting E, et al
    Care cascade of patients with Hepatitis C and HIV identified by Emergency Department screening.
    J Viral Hepat. 2021 May 1. doi: 10.1111/jvh.13529.
    PubMed     Abstract available


  208. LEE J, Kim GA, Kim HJ, Cho S, et al
    Tenofovir Disoproxil Fumarate on the Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Failure to Preceding Treatments: A Nationwide Cohort Study.
    J Viral Hepat. 2021 May 1. doi: 10.1111/jvh.13530.
    PubMed     Abstract available


    April 2021
  209. KUMADA T
    Reply to: 'Long-term prognosis with or without nucleot(s)ide analogue therapy in hepatitis B virus-related decompensated cirrhosis'.
    J Viral Hepat. 2021 Apr 28. doi: 10.1111/jvh.13514.
    PubMed    


  210. CHEN H, Ding X, Liao G, Xia M, et al
    Hepatitis B surface antigen kinetics after discontinuation of and retreatment with oral antivirals in non-cirrhotic HBeAg-positive chronic hepatitis B.
    J Viral Hepat. 2021 Apr 26. doi: 10.1111/jvh.13526.
    PubMed     Abstract available


  211. CALVARUSO V, Petta S, Cacciola I, Cabibbo G, et al
    Liver and Cardiovascular Mortality After Hepatitis C Virus Eradication by DAA: data from RESIST-HCV Cohort.
    J Viral Hepat. 2021 Apr 25. doi: 10.1111/jvh.13523.
    PubMed     Abstract available


  212. FIMMEL CJ, Khan MQ, Belopolsky Y, Imas P, et al
    Sustained and cumulative impact of an electronic medical record-based alert on a hepatitis C birth cohort screening program.
    J Viral Hepat. 2021 Apr 25. doi: 10.1111/jvh.13524.
    PubMed     Abstract available


  213. HERNANDEZ C, Trujillo D, Turner CM, Sicro S, et al
    Reaching trans-women in San Francisco for efforts to eliminate hepatitis C.
    J Viral Hepat. 2021 Apr 24. doi: 10.1111/jvh.13521.
    PubMed     Abstract available


  214. YU W, Ji H, Long F, Chen S, et al
    Inhibition of Hepatitis E Virus Replication by Zinc-Finger Antiviral Protein synergizes with IFN-beta.
    J Viral Hepat. 2021 Apr 24. doi: 10.1111/jvh.13522.
    PubMed     Abstract available


  215. ANUGWOM C, Campbell C, Debes JD
    Assessment of subclinical effects of Hepatitis E virus infection in the United States.
    J Viral Hepat. 2021 Apr 24. doi: 10.1111/jvh.13519.
    PubMed     Abstract available


  216. COOPER SL, King WC, Mogul DB, Ghany MG, et al
    Clinical Significance of Quantitative e Antigen in a Cohort of Hepatitis B Virus Infected Children and Adults in North America.
    J Viral Hepat. 2021 Apr 24. doi: 10.1111/jvh.13520.
    PubMed     Abstract available


  217. MOKAYA J, Vasylyeva TI, Barnes E, Ansari MA, et al
    Global prevalence and phylogeny of hepatitis B virus (HBV) drug and vaccine resistance mutations.
    J Viral Hepat. 2021 Apr 24. doi: 10.1111/jvh.13525.
    PubMed     Abstract available


  218. GOUTZAMANIS S, Spelman T, Harney B, Dietze P, et al
    Patient-reported outcomes of the Treatment and Prevention Study: A real-world community-based trial of direct-acting antivirals for hepatitis C among people who inject drugs.
    J Viral Hepat. 2021 Apr 20. doi: 10.1111/jvh.13516.
    PubMed     Abstract available


  219. KAMALAPIRAT T, Yingcharoen K, Ungtrakul T, Soonklang K, et al
    Assessing Risk Scores for Predicting Hepatocellular Carcinoma in Thai Patients with Chronic Hepatitis B.
    J Viral Hepat. 2021 Apr 20. doi: 10.1111/jvh.13517.
    PubMed     Abstract available


  220. SHEN DT, Han PC, Ji DZ, Chen HY, et al
    Epidemiology estimates of hepatitis D in individuals co-infected with HIV and HBV, 2002-2018: a systematic review and meta-analysis.
    J Viral Hepat. 2021 Apr 20. doi: 10.1111/jvh.13512.
    PubMed     Abstract available


  221. HARTARD C, Fenaux H, Gentilhomme A, Murray JM, et al
    Variability in molecular characteristics of Hepatitis E Virus quasispecies could modify viral surface properties and transmission.
    J Viral Hepat. 2021 Apr 20. doi: 10.1111/jvh.13513.
    PubMed     Abstract available


  222. WENG F
    Comment on "Long-term prognosis with or without nucleot(s)ide analogue therapy in hepatitis B virus-related decompensated cirrhosis".
    J Viral Hepat. 2021 Apr 19. doi: 10.1111/jvh.13515.
    PubMed     Abstract available


  223. DZINGIRAI B, Katsidzira L, Matyanga CMJ, Postma MJ, et al
    Progress on the elimination of viral hepatitis in Zimbabwe: A review of the policies, strategies and challenges.
    J Viral Hepat. 2021 Apr 2. doi: 10.1111/jvh.13510.
    PubMed     Abstract available


  224. YAO K, Liu J, Wang J, Yan X, et al
    Distribution and clinical characteristics of patients with chronic hepatitis B virus infection in the gray zone.
    J Viral Hepat. 2021 Apr 2. doi: 10.1111/jvh.13511.
    PubMed     Abstract available


  225. ZHANG Y, Xu W, Zhu X, Li X, et al
    The 48-week safety and therapeutic effects of tenofovir alafenamide in hbv-related acute-on-chronic liver failure: A prospective cohort study.
    J Viral Hepat. 2021;28:592-600.
    PubMed     Abstract available


  226. LEE TH, Chan A, Bryan W, Park L, et al
    Proton pump inhibitor usage reduces sustained viral response rates for veterans with HIV/HCV coinfection on ledipasvir/sofosbuvir: a real-world study from a multicentre VA cohort.
    J Viral Hepat. 2021;28:630-636.
    PubMed     Abstract available


    March 2021
  227. PERICOT-VALVERDE I, Rennert L, Heo M, Akiyama MJ, et al
    Rates of perfect self-reported adherence to direct-acting antiviral therapy and its correlates among people who inject drugs on medications for opioid use disorder: The PREVAIL study.
    J Viral Hepat. 2021;28:548-557.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: